# Agenus Inc: financial statements, quarterly

AGEN · Nasdaq · CIK 1098972 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/agen.md) · [Financials](/companies/agen/financials.md) · [Filings](/companies/agen/filings.md) · [Insiders](/companies/agen/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/agen/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [24.3](/filings/0000950170-24-125608.md) | [83.8 d](/filings/0001193125-26-108632.md) | [28.0](/filings/0000950170-25-069396.md) | [23.5](/filings/0000950170-25-106633.md) | [25.1](/filings/0001193125-25-274554.md) | [26.8 d](/filings/0001193125-26-108632.md) | [24.1](/filings/0001193125-26-217082.md) | [25.7](/filings/0001193125-26-340363.md) | [30.2](/filings/0001193125-25-274554.md) | [34.2 d](/filings/0001193125-26-108632.md) | [33.7](/filings/0001193125-26-217082.md) | [34.5](/filings/0001193125-26-340363.md) |
| Cost of revenue | $m | [0.3](/filings/0000950170-24-125608.md) | [0.3 d](/filings/0001193125-26-108632.md) | [0.1](/filings/0000950170-25-069396.md) | [0.1](/filings/0000950170-25-106633.md) | [0.1](/filings/0001193125-25-274554.md) | [0.1 d](/filings/0001193125-26-108632.md) | [0.1](/filings/0001193125-26-217082.md) | [0.2](/filings/0001193125-26-340363.md) | [0.6](/filings/0001193125-25-274554.md) | [0.0 d](/filings/0001193125-26-108632.md) | [0.0](/filings/0001193125-26-217082.md) | [0.0](/filings/0001193125-26-340363.md) |
| Research and development | $m | [51.4](/filings/0000950170-24-125608.md) | [66.7 d](/filings/0001193125-26-108632.md) | [43.9](/filings/0000950170-25-069396.md) | [36.8](/filings/0000950170-25-106633.md) | [41.1](/filings/0001193125-25-274554.md) | [33.8 d](/filings/0001193125-26-108632.md) | [21.5](/filings/0001193125-26-217082.md) | [26.7](/filings/0001193125-26-340363.md) | [23.6](/filings/0001193125-25-274554.md) | [7.5 d](/filings/0001193125-26-108632.md) | [11.8](/filings/0001193125-26-217082.md) | [14.8](/filings/0001193125-26-340363.md) |
| Operating income | $m | [(46.3)](/filings/0000950170-24-125608.md) | [(4.2) d](/filings/0001193125-26-108632.md) | [(32.9)](/filings/0000950170-25-069396.md) | [(30.2)](/filings/0000950170-25-106633.md) | [(31.5)](/filings/0001193125-25-274554.md) | [(25.9) d](/filings/0001193125-26-108632.md) | [(13.3)](/filings/0001193125-26-217082.md) | [(16.7)](/filings/0001193125-26-340363.md) | [(4.5)](/filings/0001193125-25-274554.md) | [14.4 d](/filings/0001193125-26-108632.md) | [15.1](/filings/0001193125-26-217082.md) | [11.3](/filings/0001193125-26-340363.md) |
| Interest expense | $m | not reported | not reported | [30.3](/filings/0000950170-25-069396.md) | [32.3](/filings/0000950170-25-106633.md) | [36.7](/filings/0001193125-25-274554.md) | [21.1 d](/filings/0001193125-26-108632.md) | [13.0](/filings/0001193125-26-217082.md) | [13.3](/filings/0001193125-26-340363.md) | [13.2](/filings/0001193125-25-274554.md) | [16.0 d](/filings/0001193125-26-108632.md) | [14.7](/filings/0001193125-26-217082.md) | [15.4](/filings/0001193125-26-340363.md) |
| Net income | $m | [(64.5)](/filings/0000950170-24-125608.md) | [(48.6) d](/filings/0001193125-26-108632.md) | [(63.5)](/filings/0001193125-25-274554.md) | [(54.8)](/filings/0001193125-25-274554.md) | [(67.2)](/filings/0001193125-25-274554.md) | [(46.8) d](/filings/0001193125-26-108632.md) | [(26.4)](/filings/0001193125-26-340363.md) | [(30.0)](/filings/0001193125-26-340363.md) | [63.9](/filings/0001193125-25-274554.md) | [(10.6) d](/filings/0001193125-26-108632.md) | [39.2](/filings/0001193125-26-340363.md) | [(0.6)](/filings/0001193125-26-340363.md) |
| Diluted EPS | $ per share | [(3.29)](/filings/0000950170-24-125608.md) | not reported | [(3.04)](/filings/0000950170-25-069396.md) | [(2.52)](/filings/0000950170-25-106633.md) | [(3.08)](/filings/0001193125-25-274554.md) | not reported | [(1.03)](/filings/0001193125-26-217082.md) | [(1.00)](/filings/0001193125-26-340363.md) | [1.94](/filings/0001193125-25-274554.md) | not reported | [1.02](/filings/0001193125-26-217082.md) | [(0.01)](/filings/0001193125-26-340363.md) |
| Basic EPS | $ per share | [(3.29)](/filings/0000950170-24-125608.md) | not reported | [(3.04)](/filings/0000950170-25-069396.md) | [(2.52)](/filings/0000950170-25-106633.md) | [(3.08)](/filings/0001193125-25-274554.md) | not reported | [(1.03)](/filings/0001193125-26-217082.md) | [(1.00)](/filings/0001193125-26-340363.md) | [2.00](/filings/0001193125-25-274554.md) | not reported | [1.03](/filings/0001193125-26-217082.md) | [(0.01)](/filings/0001193125-26-340363.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [106](/filings/0000950170-24-125608.md) | [76.1](/filings/0001193125-26-108632.md) | [52.9](/filings/0000950170-25-069396.md) | [93.7](/filings/0000950170-25-106633.md) | [44.8](/filings/0001193125-25-274554.md) | [40.4](/filings/0001193125-26-340363.md) | [18.5](/filings/0001193125-26-217082.md) | [9.5](/filings/0001193125-26-340363.md) | [3.5](/filings/0001193125-25-274554.md) | [3.0](/filings/0001193125-26-340363.md) | [35.0](/filings/0001193125-26-217082.md) | [18.7](/filings/0001193125-26-340363.md) |
| Current assets | $m | [126](/filings/0000950170-23-062051.md) | [112](/filings/0000950170-25-040289.md) | [60.4](/filings/0000950170-24-053951.md) | [100](/filings/0000950170-24-093937.md) | [50.2](/filings/0000950170-24-125608.md) | [45.6](/filings/0001193125-26-108632.md) | [23.1](/filings/0000950170-25-069396.md) | [13.3](/filings/0000950170-25-106633.md) | [134](/filings/0001193125-25-274554.md) | [133](/filings/0001193125-26-340363.md) | [95.3](/filings/0001193125-26-217082.md) | [78.8](/filings/0001193125-26-340363.md) |
| Total assets | $m | [335](/filings/0000950170-23-062051.md) | [314](/filings/0000950170-25-040289.md) | [257](/filings/0000950170-24-053951.md) | [292](/filings/0000950170-24-093937.md) | [238](/filings/0000950170-24-125608.md) | [226](/filings/0001193125-26-108632.md) | [200](/filings/0000950170-25-069396.md) | [185](/filings/0000950170-25-106633.md) | [234](/filings/0001193125-25-274554.md) | [227](/filings/0001193125-26-340363.md) | [186](/filings/0001193125-26-217082.md) | [173](/filings/0001193125-26-340363.md) |
| Current liabilities | $m | [198](/filings/0000950170-23-062051.md) | [256](/filings/0000950170-25-040289.md) | [256](/filings/0000950170-24-053951.md) | [271](/filings/0000950170-24-093937.md) | [271](/filings/0000950170-24-125608.md) | [221](/filings/0001193125-26-108632.md) | [208](/filings/0000950170-25-069396.md) | [235](/filings/0000950170-25-106633.md) | [287](/filings/0001193125-25-274554.md) | [323](/filings/0001193125-26-340363.md) | [249](/filings/0001193125-26-217082.md) | [232](/filings/0001193125-26-340363.md) |
| Long-term debt | $m | [12.7](/filings/0000950170-23-062051.md) | [12.8](/filings/0000950170-25-040289.md) | [0.0](/filings/0000950170-24-053951.md) | [0.0](/filings/0000950170-24-093937.md) | [0.0](/filings/0000950170-24-125608.md) | [30.5](/filings/0001193125-26-108632.md) | [32.8](/filings/0000950170-25-069396.md) | [23.2](/filings/0000950170-25-106633.md) | [23.6](/filings/0001193125-25-274554.md) | [0.0](/filings/0001193125-26-108632.md) | [30.2](/filings/0001193125-26-217082.md) | [30.1](/filings/0001193125-26-340363.md) |
| Current portion of debt | $m | [0.4](/filings/0000950170-23-062051.md) | [0.1](/filings/0000950170-25-040289.md) | [13.6](/filings/0000950170-24-053951.md) | [13.4](/filings/0000950170-24-093937.md) | [13.4](/filings/0000950170-24-125608.md) | [2.7](/filings/0001193125-26-108632.md) | [0.7](/filings/0000950170-25-069396.md) | [10.7](/filings/0000950170-25-106633.md) | [10.6](/filings/0001193125-25-274554.md) | [44.7](/filings/0001193125-26-340363.md) | [30.2](/filings/0001193125-26-217082.md) | [30.1](/filings/0001193125-26-340363.md) |
| Shareholders' equity | $m | [(129)](/filings/0000950170-23-062051.md) | [(160)](/filings/0000950170-25-040289.md) | [(201)](/filings/0000950170-24-053951.md) | [(241)](/filings/0000950170-24-093937.md) | [(292)](/filings/0000950170-24-125608.md) | [(326)](/filings/0001193125-26-108632.md) | [(342)](/filings/0000950170-25-069396.md) | [(355)](/filings/0000950170-25-106633.md) | [(274)](/filings/0001193125-25-274554.md) | [(271)](/filings/0001193125-26-340363.md) | [(221)](/filings/0001193125-26-217082.md) | [(199)](/filings/0001193125-26-340363.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(65.2) d](/filings/0000950170-24-125608.md) | [(40.4) d](/filings/0001193125-26-108632.md) | [(38.2)](/filings/0000950170-25-069396.md) | [(38.2) d](/filings/0000950170-25-106633.md) | [(53.3) d](/filings/0001193125-25-274554.md) | [(28.7) d](/filings/0001193125-26-108632.md) | [(25.6)](/filings/0001193125-26-217082.md) | [(20.2) d](/filings/0001193125-26-340363.md) | [(14.7) d](/filings/0001193125-25-274554.md) | [(16.6) d](/filings/0001193125-26-108632.md) | [(36.0)](/filings/0001193125-26-217082.md) | [(31.2) d](/filings/0001193125-26-340363.md) |
| Capital expenditure | $m | [3.5 d](/filings/0000950170-24-125608.md) | [0.2 d](/filings/0001193125-26-108632.md) | [0.0](/filings/0000950170-25-069396.md) | [0.5 d](/filings/0000950170-25-106633.md) | [0.0 d](/filings/0001193125-25-274554.md) | [0.1 d](/filings/0001193125-26-108632.md) | [0.0](/filings/0001193125-26-217082.md) | [0.0 d](/filings/0001193125-26-340363.md) | [0.0 d](/filings/0001193125-25-274554.md) | [0.0 d](/filings/0001193125-26-108632.md) | [0.0](/filings/0001193125-26-217082.md) | [0.0 d](/filings/0001193125-26-340363.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.3](/filings/0000950170-23-062051.md) | [15.9](/filings/0000950170-24-053951.md) | [17.6](/filings/0000950170-24-093937.md) | [18.9](/filings/0000950170-24-125608.md) | [20.4](/filings/0000950170-25-069396.md) | [21.1](/filings/0000950170-25-106633.md) | [21.6](/filings/0001193125-25-274554.md) | [24.5](/filings/0001193125-26-217082.md) | [28.1](/filings/0001193125-26-340363.md) | [32.9](/filings/0001193125-25-274554.md) | [38.3](/filings/0001193125-26-217082.md) | [41.3](/filings/0001193125-26-340363.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 45,020,407 at 2026-08-04, from the cover of the [10-Q filed 2026-08-07](/filings/0001193125-26-340363.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.